Psychological and biological mechanisms of cytokine induced depression

Epidemiologia e Psichiatria Sociale

Volumn 19, Issue 2, 2010, Pages 98-102

  Hepgul, Nilay ^a   Mondelli, Valeria ^a   Pariante, Carmine M ^a  

^a James Black Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE;

DEPRESSION; EDITORIAL; HUMAN; IMMUNOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

CYTOKINES; DEPRESSION; HUMANS; INTERFERON-ALPHA;

EID: 77957758183     PISSN: 1121189X     EISSN: 20381816     Source Type: Journal    
DOI: 10.1705/496.5880     Document Type: Review

References (35)

1. Agarwal K., Cross T.I. & Gore C. (2007). Chronic hepatitis C. British Medical Journal 334, 54-55.
2. Asnis G.M. & De La Garza (2006). Interferon induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology and treatment approaches. Journal of Clinical Gastroenterology 40, 322-335.
3. Bhagwagar Z., Hafizi S. & Cowen P.J. (2005). Increased salivary cortisol after waking in depression. Psychopharmacology 182, 54-57.
4. Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., Meltzer H. & Maes M. (2002). Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. Journal of Clinical Psychopharmacology 22, 86-90.
5. Bouhuys A.L., Flentge F., Oldehinkel A.J. & van den Berg M.D. (2004). Potential psychosocial mechanisms linking depression to immune function in elderly subjects. Psychiatry Research 127, 237-245.
6. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C. , Miyazaki C., Alexander N., Hotopf M., Cleare A.J. , Norris S., Cassidy E., Aitchison K.J. , Miller A.H. & Pariante C.M. (2009). Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferonalpha and ribavirin treatment. Molecular Psychiatry 14, 1095-1104.
7. Capuron L. & Miller A.H. (2004). Cytokines and psychopathology: Lessons from interferon-alpha. Biological Psychiatry 65, 819-824.
8. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B. & Miller A.H. (2002). Neurobehavioural effects on interferon-alpha in cancer patients: Phenomology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26, 643-652.
9. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B. & Miller A.H. (2003). Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. American Journal of Psychiatry 160, 1342-1345.
10. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., H.L. Harrington, J. McClay, J. Mill, J. Martin, A. Braithwaite & R. Poulton (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389.
11. Danese A., Moffitt T.E., Pariante C.M., Ambler A., Poulton R. & Caspi A. (2008). Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Archives of General Psychiatry 65:409-415.
12. Dantzer R., O'Conner J.C., Freund G.G., Johnson R.W. & Kelley K.W. (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. Nature Reviews Neuroscience 9, 46-56.
13. Evans D.L., Charney D.S., Lewis L., Golden R.N., Gorman J.M., Krishnan K., Nemeroff C., Bremner J., Carney R. & Coyne J. (2005). Mood disorders in the medically ill: Scientific review and recommendations. Biological Psychiatry 58, 175-189.
14. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., Keck P.E. Jr, Marangell L.B., Richardson A.J., Lake J. & Stoll A.L. (2006). Omega-3 fatty acids: Evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry 67, 1954-1967.
15. Hunt C.M., Dominitz J.A., Philipis-Bute B., Waters B., Blasi U. & Williams D.M. (1997). Effect of interferon-alpha treatment of chronic hepatitis C on health related quality of life. Digestive Diseases and Sciences 42, 2482-2486.
16. Kozak W., Soszynski D., Rudolph K., Conn C.A. & Kluger M.J. (1997). Dietary n-3 fatty acids differentially affect sickness behavior in mice during local and systemic inflammation. American Journal of Physiology 272, 1298-1307.
17. Lotrich F.E., Rabinovitz M., Gironda P. & Pollock B.G. (2007). Depression following pegylated interferon-alpha: Characteristics and vulnerability. Journal of Psychosomatic Research 63, 131-135.
18. Miller A.H. (2009). Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface. Brain, Behaviour and Immunity 23, 149-158.
19. Morasco B.J., Rifai M.A., Loftis J.M., Indest D.W., Moles J.K. & Hauser P. (2007). A randomized trial of paroxetine to prevent interferon- alpha-induced depression in patients with hepatitis C. Journal of Affective Disorders 103, 83-90.
20. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S, Pearce B.D., Landry J., Glover S., McDaniel J.S. & Nemeroff C.B. (2001). Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: Preliminary findings. American Journal of Psychiatry 158, 1252-1257.
21. Myint A.M., O'Mahony S., Kubera M., Kim Y.K., Kenny C., Kaim- Basta A., Steinbusch H.W.M. & Leonard B.E. (2007). Role of paroxetine in interferon-alpha-induced immune and behavioural changes in male Wistar rats. Journal of Psychopharmacology 21, 841-850.
22. Pariante C.M. (2004). Glucocorticoid receptor function in vitro in patients with major depression. Stress 7, 209-219.
23. Pariante C.M. & Lightman S.L. (2008). The HPA axis in major depression: Classical theories and new developments. Trends in Neuroscience 31, 464-468.
24. Pariante C.M., Orru M.G., Baita A., Farci M.G. & Carpiniello B. (1999). Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 354, 131-132.
25. Pariante C.M., Landau S. & Carpiniello B. (2002). Interferon alfainduced adverse effects in patients with a psychiatric diagnosis. New England Journal of Medicine 347, 148-149.
26. Raison C.L., Capuron L. & Miller A.H. (2006). Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends in Immunlogy 27, 24-31.
27. Raison C.L., Woolwine B.J., Demetrashvili M.F., Borisov A.S., Weinreib R., Staab J.P., Zajecka J.M., Bruno C.J., Henderson M.A., Reinus J.F., Evans D.L., Asnis G.M. & Miller A.H. (2007). Paroxetine for prevention of depressive symptoms induced by interferon- alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics 25, 1163-1174.
28. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G. & Miller A.H. (2008). Interferon-á effects on diurnal hypothalamicpituitary- adrenal axis activity: Relationship with proinflammatory cytokines and behaviour. Molecular Psychiatry, June 2 [Epub ahead of print].
29. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B., Vogt G., Massung B. & Miller A. (2009). Activation of central nervous system inflammatory pathways by interferonalpha: Relationship to monoamines and depression. Biological Psychiatry 65, 296-303.
30. Su K.P., Huang S.Y., Chiu T.H., Huang K.C., Huang C.L., Chang H.C. & Pariante C.M. (in press). Phospholipase A2 and cyclo-oxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biological Psychiatry [epub ahead of print].
31. Weinrieb R.M., Auriacombe M., Lynch K.G., Chang K.M. & Lewis J.D. (2003). A critical review of selective serotonin reuptake inhibitor-associated bleeding: Balancing the risk of treating hepatitis C-infected patients. Journal of Clinical Psychiatry 64, 1502-1510.
32. Wichers M. & Maes M. (2002). The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. International Journal of Neuropsychopharmacology 5, 375-388.
33. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpé S. & Maes, M. (2005). IDO and interferon-alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Molecular Psychiatry 10, 538-544.
34. Wichers M.C., Kenis G., Koek G.H., Robaeys G., Nicolson N.A. & Maes M. (2007). Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. Journal of Psychosomatic Research 62, 207-214.
35. Wise M. G. & Taylor S. E. (1990). Anxiety and mood disorders in medically ill patients. Journal of Clinical Psychiatry 51, 27-32.